Biogen also markets Avonex and Tysabri to treat relapsing-remitting MS, the most common kind of MS.

Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis.

Mapi's drug is being developed to treat relapsing-remitting MS - marked by relapses that last at least 24 hours, followed by a remission.

We describe FDO data and long-term cardiac tolerability in a cohort of fingolimod- treated relapsing MS patients.

Careful follow-up of fingolimod- treated relapsing-remitting multiple sclerosis patients is warranted as sympathetic predominance associates generally with impaired outcome.ClinicalTrials.cov: NCT01704183.